Key Points
-
Reuse of the same anticancer therapy following disease progression is often considered to be futile owing to drug resistance; however, many cancers show sensitivity to therapy reintroduction after disease progression
-
Spontaneous, reversible and epigenetic resistance mechanisms might explain the retreatment phenomenon; alternatively, cancer cells might proliferate independently of drug resistance
-
Selection of drug-resistant clones is not necessarily a major contributor to response to therapy in many patients
-
Drug resistance definitions need to be re-evaluated; for example, disease progression based on RECIST criteria might be a poor indicator of drug resistance and when to change a course of treatment
-
Applying transient drug-resistance mechanisms to clinical practice could offer advantages over traditional therapy regimens, including increased therapeutic options, reduced costs, and improvements in quality of life, without compromising efficacy
Abstract
The established dogma in oncology for managing recurrent or refractory disease dictates that therapy is changed at disease progression, because the cancer is assumed to have become drug-resistant. Drug resistance, whether pre-existing or acquired, is largely thought to be a stable and heritable process; thus, reuse of therapeutic agents that have failed is generally contraindicated. Over the past few decades, clinical evidence has suggested a role for unstable, non-heritable mechanisms of acquired drug resistance pertaining to chemotherapy and targeted agents. There are many examples of circumstances where patients respond to reintroduction of the same therapy (drug rechallenge) after a drug holiday following disease relapse or progression during therapy. Additional, albeit limited, evidence suggests that, in certain circumstances, continuing a therapy beyond disease progression can also have antitumour activity. In this Review, we describe the anticancer agents used in these treatment strategies and discuss the potential mechanisms explaining the apparent tumour re-sensitization with reintroduced or continued therapy. The extensive number of malignancies and drugs that challenge the custom of permanently switching to different drugs at each line of therapy warrants a more in-depth examination of the definitions of disease progression and drug resistance and the resulting implications for patient care.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Goldie, J. H. & Coldman, A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 63, 1727–1733 (1979).
Greaves, M. & Maley, C. C. Clonal evolution in cancer. Nature 481, 306–313 (2012).
Frank, N. Y., Schatton, T. & Frank, M. H. The therapeutic promise of the cancer stem cell concept. J. Clin. Invest. 120, 41–50 (2010).
Ling, V. & Thompson, L. H. Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J. Cell Physiol. 83, 103–116 (1974).
Haber, D. A. & Schimke, R. T. Unstable amplification of an altered dihydrofolate reductase gene associated with double-minute chromosomes. Cell 26, 355–362 (1981).
Juliano, R. L. & Ling, V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 455, 152–162 (1976).
Yu, M., Ocana, A. & Tannock, I. F. Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit? Cancer Metastasis Rev. 32, 211–227 (2013).
Nardi, V., Azam, M. & Daley, G. Q. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr. Opin. Hematol. 11, 35–43 (2004).
Engelman, J. A. & Jänne, P. A. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin. Cancer Res. 14, 2895–2899 (2008).
Kan, Z. et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466, 869–873 (2010).
Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546–1558 (2013).
Cara, S. & Tannock, I. F. Retreatment of patients with the same chemotherapy: implications for clinical mechanisms of drug resistance. Ann. Oncol. 12, 23–27 (2001).
Colombo, N. & Gore, M. Treatment of recurrent ovarian cancer relapsing 6–12 months post platinum-based chemotherapy. Crit. Rev. Oncol. Hematol. 64, 129–138 (2007).
Hejna, M. et al. Reinduction therapy with the same cytostatic regimen in patients with advanced colorectal cancer. Br. J. Cancer 78, 760–764 (1998).
Simon, G. R. et al. Small cell lung cancer. Chest 123 (Suppl.), 259S–271S (2003).
Kreso, A. et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 339, 543–548 (2013).
Saltz, L. B. et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. 343, 905–914 (2000).
Grothey, A. et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J. Clin. Oncol. 26, 5326–5334 (2008).
Grothey, A. Reintroduction of oxaliplatin: a viable approach to the long-term management of metastatic colorectal cancer. Oncology 79, 389–399 (2010).
Maindrault-Gœbel, F. et al. Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. Ann. Oncol. 15, 1210–1214 (2004).
Fornaro, L. et al. Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen. Clin. Colorectal Cancer 11, 71–76 (2012).
Maughan, T. S. et al. Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial. Lancet 361, 457–464 (2003).
Tournigand, C. et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer--a GERCOR study. J. Clin. Oncol. 24, 394–400 (2006).
Chibaudel, B. et al. Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J. Clin. Oncol. 27, 5727–5733 (2009).
de Gramont, A. et al. Reintroduction of oxaliplatin is associated with improved survival in advanced colorectal cancer. J. Clin. Oncol. 25, 3224–3229 (2007).
de Gramont, A. H. et al. Definition of oxaliplatin sensitivity in patients with advanced colorectal cancer previously treated with oxaliplatin-based therapy [abstract]. J. Clin. Oncol. 27 (Suppl.), a4024 (2009).
Adams, R. A. et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol. 12, 642–653 (2011).
Seruga, B. & Tannock, I. F. Intermittent androgen blockade should be regarded as standard therapy in prostate cancer. Nat. Clin. Pract. Oncol. 5, 574–576 (2008).
Beer, T. M., Garzotto, M., Henner, W. D., Eilers, K. M. & Wersinger, E. M. Intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br. J. Cancer 89, 968–970 (2003).
Heck, M. M. et al. Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer. BJU Int. 110, E635–E640 (2012).
Eymard, J. et al. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU Int. 106, 974–978 (2010).
Ansari, J. et al. Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience. Oncol. Rep. 20, 891–896 (2008).
Jankovic, B., Beardsley, E. & Chi, K. N. Rechallenge with docetaxel as second-line chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) after previous docetaxel: A population based analysis [abstract]. ASCO Genitourinary Cancers Symp. a196 (2008).
Loriot, Y. et al. The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer. Eur. J. Cancer 46, 1770–1772 (2010).
Beer, T. M. et al. Intermittent chemotherapy in patients with metastatic androgen–independent prostate cancer. Cancer 112, 326–330 (2008).
Beer, T. M., Garzotto, M., Henner, W. D., Eilers, K. M. & Wersinger, E. M. Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer. Br. J. Cancer 91, 1425–1427 (2004).
Di Lorenzo, G. et al. Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU Int. 107, 234–239 (2011).
US National Library of Medicine. ClinicalTrials.gov [online], (2010).
Blay, J. Y. et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J. Clin. Oncol. 25, 1107–1113 (2007).
Patrikidou, A. et al. Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial. Ann. Oncol. 24, 1087–1093 (2013).
Le Cesne, A. et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol. 11, 942–949 (2010).
Ray-Coquard, I. L. et al. Risk of relapse with imatinib (IM) discontinuation at 5 years in advanced GIST patients: Results of the prospective BRF14 randomised phase III study comparing interruption versus continuation of IM at 5 years of treatment: a French Sarcoma Group Study [abstract]. J. Clin. Oncol. 28 (Suppl.), a10032 (2010).
Reichardt, P. et al. Response to imatinib rechallenge of GIST that recurs following completion of adjuvant imatinib treatment—the first analysis in the SSGXVIII/AIO trial patient population [abstract 31LBA]. Eur. J. Cancer 47, 15 (2011).
Mahon, F. et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 11, 1029–1035 (2010).
Ross, M. D. et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122, 512–522 (2013).
Goh, H. et al. Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy. Leuk. Lymphoma 50, 944–951 (2009).
Wick, A. et al. Rechallenge with temozolomide in patients with recurrent gliomas. J. Neurol. 256, 734–741 (2009).
Gaviani, P. et al. Rechallenge with temozolomide in recurrent glioma. Neurol. Sci. 32 (Suppl. 2), S247–S249 (2011).
Perry, J. R., Rizek, P., Cashman, R., Morrison, M. & Morrison, T. Temozolomide rechallenge in recurrent malignant glioma by using a continuous temozolomide schedule: the “rescue” approach. Cancer 113, 2152–2157 (2008).
Jauch, T., Hau, P. & Bogdahn, U. Re-challenge with temozolomide (TMZ) at recurrence in high-grade gliomas [abstract]. J. Clin. Oncol. 25 (Suppl. 18), a2034 (2007).
Balmaceda, C. et al. Treatment with temozolomide for malignant gliomas: Is rechallenge with alternative dosing regimens successful [abstract]? J. Clin. Oncol. 24 (Suppl.), a11514C (2006).
Franceschi, E. et al. Salvage temozolomide for prior temozolomide responders. Cancer 104, 2473–2476 (2005).
Kong, D. S. et al. A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol. Rep. 16, 1117–1121 (2006).
Strik, H. M. et al. Rechallenge with temozolomide with different scheduling is effective in recurrent malignant gliomas. Mol. Med. Rep. 1, 863–867 (2008).
Perry, J. R. et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J. Clin. Oncol. 28, 2051–2057 (2010).
US National Library of Medicine. ClinicalTrials.gov [online], (2012).
Naing, A. & Kurzrock, R. Chemotherapy resistance and retreatment: a dogma revisited. Clin. Colorectal Cancer 9, E1–E4 (2010).
Santini, D. et al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? Ann. Oncol. 23, 2313–2318 (2012).
Oxnard, G. R. & Miller, V. A. Use of erlotinib or gefitinib as initial therapy in advanced NSCLC. Oncology (Williston Park). 24, 392–399 (2010).
Lee, D. H. et al. Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment. Ann. Oncol. 19, 2039–2042 (2008).
Kurata, T. et al. Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance. Ann. Oncol. 15, 173–174 (2004).
Yano, S. et al. Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases. Oncol. Res. 15, 107–111 (2005).
Wong, A. S., Seto, K. Y., Chin, T. M. & Soo, R. A. Lung cancer response to gefitinib, then erlotinib, then gefitinib again. J. Thorac. Oncol. 3, 1077–1078 (2008).
Yokouchi, H. et al. Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer. BMC Cancer 7, 51 (2007).
Tomizawa, Y. et al. Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy. Lung Cancer 68, 269–272 (2010).
Asahina, H. et al. Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib. Oncology 79, 423–429 (2010).
Oh, I. J., Ban, H. J., Kim, K. S. & Kim, Y. C. Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study. Lung Cancer 77, 121–127 (2012).
Guo, R. et al. Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer. BMC Cancer 11, 90 (2011).
Becker, A. et al. Retreatment with erlotinib: regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment. Eur. J. Cancer 47, 2603–2606 (2011).
Yoo, S. J. et al. Second complete remission of relapsed stage IV non-small cell lung cancer following retreatment. Tuberc. Respir. Dis. (Seoul) 72, 381–385 (2012).
Namba, Y. et al. Does gefitinib re-challenge or treatment beyond progression (TBP) prolong survival of NSCLC patients? Real world evidence from gefitinib treatment responders [abstract]. Ann. Oncol. 23 (Suppl. 9), a1318 (2012).
Sawaki, A. et al. Impact of imatinib plus best supportive care in imatinib- and sunitinib-exposed patients with refractory advanced gastrointestinal stromal tumor [abstract]. J. Clin. Oncol. 28 (Suppl.), a10064 (2010).
Italiano, A. et al. Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib. Ann. Surg. Oncol. 19, 1551–1559 (2012).
Kang, Y. K. et al. Randomized phase III trial of imatinib (IM) rechallenge versus placebo (PL) in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) after failure of at least both IM and sunitinib (SU): RIGHT study [abstract]. J. Clin. Oncol. 31 (Suppl.), aLBA10502 (2013).
National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Soft tissue sarcoma. Version 2013.1 [online], (2013).
Agulnik, M. & Giel, J. L. Understanding rechallenge and resistance in the tyrosine kinase inhibitor era: imatinib in gastrointestinal stromal tumor. Am. J. Clin. Oncol. http://dx.doi.org/10.1097/COC.0b013e31824be3d6.
Escudier, B., Szczylik, C., Porta, C. & Gore, M. Treatment selection in metastatic renal cell carcinoma: expert consensus. Nat. Rev. Clin. Oncol. 9, 327–337 (2012).
Wörns, M. A. et al. Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment. Oncology 79, 85–92 (2010).
Zama, I. N. et al. Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer 116, 5400–5406 (2010).
Grünwald, V. et al. Efficacy of sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCC. Onkologie 34, 310–314 (2011).
Nozawa, M. et al. Sorafenib rechallenge in patients with metastatic renal cell carcinoma. BJU Int. 110, E228–E234 (2012).
Fumagalli, E. et al. Sunitinib rechallenge in two advanced GIST patients after third-line anti-tyrosine kinase therapy [abstract]. J. Clin. Oncol. 28 (Suppl.), e20519 (2010).
Bracci, R., Maccaroni, E. & Cascinu, S. Transient sunitinib resistance in gastrointestinal stromal tumors. N. Engl. J. Med. 368, 2042–2043 (2013).
Tripathy, D. et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J. Clin. Oncol. 22, 1063–1070 (2004).
Petrelli, F. & Barni, S. A pooled analysis of 2618 patients treated with trastuzumab beyond progression for advanced breast cancer. Clin. Breast Cancer 13, 81–87 (2013).
Cancello, G. et al. Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. Breast Cancer Res. 10, R60 (2008).
Campiglio, M. et al. Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study. Breast Cancer Res. Treat. 128, 147–154 (2011).
Extra, J. M. et al. Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. Oncologist 15, 799–809 (2010).
von Minckwitz, G. et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03–05 study. J. Clin. Oncol. 27, 1999–2006 (2009).
Blackwell, K. L. et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J. Clin. Oncol. 28, 1124–1130 (2010).
Blackwell, K. L. et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J. Clin. Oncol. 30, 2585–2592 (2012).
Pegram, M. & Liao, J. Trastuzumab treatment in multiple lines: current data and future directions. Clin. Breast Cancer 12, 10–18 (2012).
Cohn, A. L. et al. Clinical outcomes in bevacizumab (BV) treated patients (pts) with metastatic colorectal cancer (mCRC): results from ARIES observational cohort study (OCS) and confirmation of BRiTE data beyond progression (BBP) [abstract]. J. Clin. Oncol. 28 (Suppl.), a4596 (2010).
Bennouna, J. et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 14, 29–37 (2013).
Reardon, D. A. et al. Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients. Br. J. Cancer 107, 1481–1487 (2012).
Konstantinopoulos, P. A., Berlin, S. T., Campos, S. M., Matulonis, U. A. & Cannistra, S. A. Bevacizumab rechallenge after first line maintenance bevacizumab. Gynecol. Oncol. 125, 510–511 (2012).
Cunningham, D. et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337–345 (2004).
Nishie, K. et al. Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations. J. Thorac. Oncol. 7, 1722–1727 (2012).
Faehling, M. et al. EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced non-small cell lung cancer: a case-control study of overall survival. Lung Cancer 80, 306–312 (2013).
US National Library of Medicine. ClinicalTrials.gov [online], (2013).
Teo, M. & McDermott, R. S. Does RECIST-defined progression correlate with lack of further sunitinib (SU) benefit in advanced renal cell carcinoma (aRCC) [abstract]? J. Clin. Oncol. 30 (Suppl.), e15093 (2012).
Miscoria, M. et al. Analysis of survival after disease progression in patients with renal cell carcinoma (RCC) who failed treatment with sunitinib [abstract]. J. Clin. Oncol. 29 (Suppl.), e15154 (2011).
Pichun, M. E. B. et al. Continuation of sunitinib following RECIST progression on first-line sunitinib [abstract]. J. Clin. Oncol. 31 (Suppl.), a4585 (2013).
Revheim, M. E. et al. Intermittent and continuous imatinib in a human GIST xenograft model carrying KIT exon 17 resistance mutation D816H. Acta Oncol. 52, 776–782 (2013).
Blagoev, K. B. et al. Relationship of the emergence of KRAS mutations and resistance to panitumumab in second-line treatment of colorectal cancer (CRC) [abstract]. J. Clin. Oncol. 31 (Suppl.), e14592 (2013).
Therasse, P. et al. New guidelines to evaluate the response to treatment in solid tumors. J. Natl Cancer Inst. 92, 205–216 (2000).
Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009).
Choi, H. et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J. Clin. Oncol. 25, 1753–1759 (2007).
Scher, H. I. et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol. 26, 1148–1159 (2008).
Wahl, R. L., Jacene, H., Kasamon, Y. & Lodge, M. A. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J. Nucl. Med. 50, 122S–150S (2009).
Wolchok, J. D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412–7420 (2009).
Lencioni, R. & Llovet, J. M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin. Liver Dis. 30, 52–60 (2010).
Kim, J. J. & Tannock, I. F. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat. Rev. Cancer 5, 516–525 (2005).
Leyvraz, S. et al. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial. J. Natl Cancer Inst. 100, 533–541 (2008).
Shulman, L. N. et al. Six cycles of doxorubicin and cyclophosphamide or paclitaxel are not superior to four cycles as adjuvant chemotherapy for breast cancer in women with zero to three positive axillary nodes: Cancer and Leukemia Group B 40101. J. Clin. Oncol. 30, 4071–4076 (2012).
Gennari, A. et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J. Clin. Oncol. 29, 2144–2149 (2011).
Pegram, M. et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18, 2241–2251 (1999).
Konecny, G. E. et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 66, 1630–1639 (2006).
Rothenberg, M. L. et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J. Clin. Oncol. 21, 2059–2069 (2003).
Chau, I. & Cunningham, D. Oxaliplatin for colorectal cancer in the United States: better late than never. J. Clin. Oncol. 21, 2049–2051 (2003).
Supino, R., Rodolfo, M., Mariani, M. & Mapelli, E. Heterogeneity and phenotypic instability of chemotherapeutic and immunologic sensitivity in murine and human melanoma cell clones. Tumori 29, 5–9 (1992).
Ferguson, P. J. & Cheng, Y. C. Phenotypic instability of drug sensitivity in a human colon carcinoma cell line. Cancer Res. 49, 1148–1153 (1989).
Cohen, A. A. et al. Dynamic proteomics of individual cancer cells in response to a drug. Science 322, 1511–1516 (2008).
Deschatrette, J. et al. Telomere dynamics determine episodes of anticancer drug resistance in rat hepatoma cells. Anticancer Drugs 15, 671–678 (2004).
Quintana, E. et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 18, 510–523 (2010).
Kobayashi, S. et al. LGR5-positive colon cancer stem cells interconvert with drug-resistant LGR5-negative cells and are capable of tumor reconstitution. Stem Cells 30, 2631–2644 (2012).
Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69–80 (2010).
He, K., Xu, T. & Goldkorn, A. Cancer cells cyclically lose and regain drug-resistant highly tumorigenic features characteristic of a cancer stem-like phenotype. Mol. Cancer Ther. 10, 938–948 (2011).
Weisberg, E. et al. Reversible resistance induced by FLT3 inhibition: a novel resistance mechanism in mutant FLT3-expressing cells. PLoS ONE 6, e25351 (2011).
Zijlstra, J. G., de Vries, E. G. & Mulder, N. H. Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res. 47, 1780–1784 (1987).
Teicher, B. A. et al. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 247, 1457–1461 (1990).
Chmielecki, J. et al. Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci. Transl. Med. 3, 90ra59 (2011).
Morales, C. et al. Dihydrofolate reductase amplification and sensitization to methotrexate of methotrexate-resistant colon cancer cells. Mol. Cancer Ther. 8, 424–432 (2009).
Zhang, L. et al. Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. PLoS ONE 6, e19144 (2011).
Hammers, H. J. et al. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol. Cancer Ther. 9, 1525–1535 (2010).
Tang, T. C. et al. Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. Neoplasia 12, 928–940 (2010).
Sabnis, G. J., Macedo, L. F., Goloubeva, O., Schayowitz, A. & Brodie, A. M. Stopping treatment can reverse acquired resistance to letrozole. Cancer Res. 68, 4518–4524 (2008).
US National Library of Medicine. ClinicalTrials.gov [online], (2012).
Wang, X. et al. High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma. J. Transl. Med. 9, 220 (2011).
Solit, D. B. et al. Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clin. Cancer Res. 11, 1983–1989 (2005).
Rimawi, M. F. et al. Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Clin. Cancer Res. 17, 1351–1361 (2011).
Das Thakur, M. et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494, 251–255 (2013).
Sequist, L. V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3, 75ra26 (2011).
Hata, A., Katakami, N., Kaji, R., Fujita, S. & Imai, Y. Does T790M disappear? Successful gefitinib rechallenge after T790M disappearance in a patient with EGFR-mutant non-small-cell lung cancer. J. Thorac. Oncol. 8, e27–e29 (2013).
Formelli, F., Rossi, C., Supino, R. & Parmiani, G. In vivo characterization of a doxorubicin resistant B16 melanoma cell line. Br. J. Cancer 54, 223–233 (1986).
Petrucci, M. T. et al. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma. Br. J. Haematol. 160, 649–659 (2013).
Fiegl, M. et al. Retreatment with alemtuzumab after a first, successful alemtuzumab treatment in B-CLL [abstract]. Blood 110, a4714 (2007).
Hrusovsky, I. et al. Bortezomib retreatment in relapsed multiple myeloma—results from a retrospective multicentre survey in Germany and Switzerland. Oncology 79, 247–254 (2010).
Shamash, J. et al. A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer. Br. J. Cancer 98, 22–24 (2008).
Palmieri, C. et al. Rechallenging with anthracyclines and taxanes in metastatic breast cancer. Nat. Rev. Clin. Oncol. 7, 561–574 (2010).
Taverna, C., Voegeli, J., Trojan, A., Olie, R. A. & von Rohr, A. Effective response with bortezomib retreatment in relapsed multiple myeloma—a multicentre retrospective survey in Switzerland. Swiss Med. Wkly 142, w13562 (2012).
Fiegl, M. et al. Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients. Ann. Hematol. 90, 1083–1091 (2011).
Sonneveld, P. et al. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The Leukaemia Group of the EORTC and the HOVON. Lancet 340, 255–259 (1992).
Miller, T. P. et al. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J. Clin. Oncol. 9, 17–24 (1991).
Sonneveld, P. et al. Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). Br. J. Haematol. 115, 895–902 (2001).
Dalton, W. S. et al. A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. A Southwest Oncology Group study. Cancer 75, 815–820 (1995).
Smith, T. J. & Hillner, B. E. Bending the cost curve in cancer care. N. Engl. J. Med. 364, 2060–2065 (2011).
Fojo, T. & Grady, C. How much is life worth: cetuximab, non–small cell lung cancer, and the $440 billion question. J. Natl Cancer Inst. 101, 1044–1048 (2009).
Muss, H. B. et al. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. N. Engl. J. Med. 325, 1342–1348 (1991).
[No authors listed] Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment. J. Clin. Oncol. 18, 3115–3124 (2000).
Guerin, E., Man, S., Xu, P. & Kerbel, R. S. A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs. Cancer Res. 73, 2743–2748 (2013).
Sivanand, S. et al. A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma. Sci. Transl. Med. 4, 137ra75 (2012).
Hashimoto, K. et al. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer. Mol. Cancer Ther. 9, 996–1006 (2010).
Koopman, M. et al. Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): the phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG) [abstract]. J. Clin. Oncol. 31 (Suppl.), a3502 (2013).
Pignata, S. et al. Extending the platinum-free interval with a non-platinum therapy in platinum-sensitive recurrent ovarian cancer. Results from the SOCRATES Retrospective Study. Oncology 71, 320–326 (2006).
Young, R. C., Chabner, B. A., Canellos, G. P., Schein, P. S. & DeVita, V. T. Maintenance chemotherapy for advanced Hodgkin's disease in remission. Lancet 1, 1339–1343 (1973).
Alexanian, R., Gehan, E., Haut, A., Saiki, J. & Weick, J. Unmaintained remissions in multiple myeloma. Blood 51, 1005–1011 (1978).
Muss, H. B., Smith, L. R. & Cooper, M. R. Tamoxifen rechallenge: response to tamoxifen following relapse after adjuvant chemohormonal therapy for breast cancer. J. Clin. Oncol. 5, 1556–1558 (1987).
Cox, R. A. & Sundar, S. Re-induction of hormone sensitivity to diethylstilboestrol in androgen refractory prostate cancer patients following chemotherapy. Br. J. Cancer 98, 238–239 (2008).
Klotz, L. H., Herr, H. W., Morse, M. J. & Whitmore, W. F. Jr. Intermittent endocrine therapy for advanced prostate cancer. Cancer 58, 2546–2550 (1986).
Acknowledgements
Grant and funding support for this Review came from the Canadian Liver Foundation (E. A. Kuczynski), the Canadian Institutes of Health Research, the Canadian Breast Cancer Foundation, the National Institutes of Health, USA (R. S. Kerbel); Mayo Clinic Cancer Center National Cancer Institute grant (D. J. Sargent, A. Grothey).
Author information
Authors and Affiliations
Contributions
E. A. Kuczynski and R. S. Kerbel researched data for the article. E. A. Kuczynski, D. J. Sargent and R. S. Kerbel wrote the article. All authors made a substantial contribution to discussion of the content, and reviewed and edited the manuscript prior to submission.
Corresponding author
Ethics declarations
Competing interests
D. J. Sargent received consulting fees from Genentech, and has associations and received consulting feeds from Abbott, Bayer, Medivation and Novartis. A. Grothey receives research support for clinical trials from the following companies: Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, Genentech, ImClone Systems/ Eli Lilly, Morphotek and Sanofi. R. S. Kerbel declares association with the following companies: Taiho Pharmaceuticals, Cerulean Pharma, MolMed sPA, Pfizer, Angiocrine Biosciences, and YM Biosciences. He has received honoraria from Roche/Genentech, Pfizer, Regeneron/Sanofi. E. A. Kuczynski declares no competing interests.
Supplementary information
Supplementary Table 1
Drug rechallenge following progression off therapy (DOC 36 kb)
Supplementary Table 2
Drug rechallenge following progression on therapy (DOCX 27 kb)
Supplementary Table 3
Continuation of treatment beyond progression, phase II and III randomized clinical trials (DOCX 27 kb)
Supplementary Text
Additional rechallenge agents (DOCX 40 kb)
Rights and permissions
About this article
Cite this article
Kuczynski, E., Sargent, D., Grothey, A. et al. Drug rechallenge and treatment beyond progression—implications for drug resistance. Nat Rev Clin Oncol 10, 571–587 (2013). https://doi.org/10.1038/nrclinonc.2013.158
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2013.158
This article is cited by
-
Decoding cancer insights: recent progress and strategies in proteomics for biomarker discovery
Journal of Proteins and Proteomics (2024)
-
Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study
BMC Cancer (2023)
-
Drug-tolerant persister cells in cancer: the cutting edges and future directions
Nature Reviews Clinical Oncology (2023)
-
Heterogeneity in leukemia cells that escape drug-induced senescence-like state
Cell Death & Disease (2023)
-
Potential role of autophagy induced by FLT3-ITD and acid ceramidase in acute myeloid leukemia chemo-resistance: new insights
Cell Communication and Signaling (2022)